Cargando…

SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity

In response to COVID-19 pandemic, the Zimbabwe government put in place various rigorous measures to curb the spread of the virus. Although roll-out and access to COVID-19 vaccines in Africa have been slow, the World Health Organization (WHO)-led COVID-19 Vaccines Global Access (COVAX) consortium and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kouamou, Vinie, Matarise, Richard, Santos, Elizabeth Dos, Elose, Nyasha, Manasa, Justen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520422/
https://www.ncbi.nlm.nih.gov/pubmed/34707756
http://dx.doi.org/10.11604/pamj.2021.39.255.30331
_version_ 1784584669459644416
author Kouamou, Vinie
Matarise, Richard
Santos, Elizabeth Dos
Elose, Nyasha
Manasa, Justen
author_facet Kouamou, Vinie
Matarise, Richard
Santos, Elizabeth Dos
Elose, Nyasha
Manasa, Justen
author_sort Kouamou, Vinie
collection PubMed
description In response to COVID-19 pandemic, the Zimbabwe government put in place various rigorous measures to curb the spread of the virus. Although roll-out and access to COVID-19 vaccines in Africa have been slow, the World Health Organization (WHO)-led COVID-19 Vaccines Global Access (COVAX) consortium and the African vaccine acquisition task team are striving to provide 720 million doses of COVID-19 vaccines to achieve 60% coverage in Africa by June, 2022. In line with this, the Zimbabwe vaccination programme commenced on the 26(th) February 2021 and as of 9(th) June 2021, approximately, 2.6% of the population have been fully vaccinated in the country. Although the COVID-19 pandemic has crippled the economy and caused significant strain on the public health system, much has been done in the country since the first case was recorded (20(th) March 2020). However, much more needs to be done to finally reach the expected 60% herd immunity by June 2022.
format Online
Article
Text
id pubmed-8520422
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-85204222021-10-26 SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity Kouamou, Vinie Matarise, Richard Santos, Elizabeth Dos Elose, Nyasha Manasa, Justen Pan Afr Med J Perspectives In response to COVID-19 pandemic, the Zimbabwe government put in place various rigorous measures to curb the spread of the virus. Although roll-out and access to COVID-19 vaccines in Africa have been slow, the World Health Organization (WHO)-led COVID-19 Vaccines Global Access (COVAX) consortium and the African vaccine acquisition task team are striving to provide 720 million doses of COVID-19 vaccines to achieve 60% coverage in Africa by June, 2022. In line with this, the Zimbabwe vaccination programme commenced on the 26(th) February 2021 and as of 9(th) June 2021, approximately, 2.6% of the population have been fully vaccinated in the country. Although the COVID-19 pandemic has crippled the economy and caused significant strain on the public health system, much has been done in the country since the first case was recorded (20(th) March 2020). However, much more needs to be done to finally reach the expected 60% herd immunity by June 2022. The African Field Epidemiology Network 2021-08-20 /pmc/articles/PMC8520422/ /pubmed/34707756 http://dx.doi.org/10.11604/pamj.2021.39.255.30331 Text en Copyright: Vinie Kouamou et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspectives
Kouamou, Vinie
Matarise, Richard
Santos, Elizabeth Dos
Elose, Nyasha
Manasa, Justen
SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
title SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
title_full SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
title_fullStr SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
title_full_unstemmed SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
title_short SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
title_sort sars-cov-2 in zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520422/
https://www.ncbi.nlm.nih.gov/pubmed/34707756
http://dx.doi.org/10.11604/pamj.2021.39.255.30331
work_keys_str_mv AT kouamouvinie sarscov2inzimbabwemilestonesandchallengesfacedtowardsachievingtheexpected60herdimmunity
AT matariserichard sarscov2inzimbabwemilestonesandchallengesfacedtowardsachievingtheexpected60herdimmunity
AT santoselizabethdos sarscov2inzimbabwemilestonesandchallengesfacedtowardsachievingtheexpected60herdimmunity
AT elosenyasha sarscov2inzimbabwemilestonesandchallengesfacedtowardsachievingtheexpected60herdimmunity
AT manasajusten sarscov2inzimbabwemilestonesandchallengesfacedtowardsachievingtheexpected60herdimmunity